NAPP PHARMACEUTICALS LIMITED

Active
Company number 03690299Private limited companyIncorporated 1998

Key figures

£14,175,000+3.0%
Net assets 2025
+3.0%
Average annual growth 2024–2025
05 m10 m15 m20242025

† NAPP PHARMACEUTICALS LIMITED filed these accounts on paper, so Companies House publishes them only as a scanned image. The figures for the years marked † were read automatically from the scan and kept only where the statements add up (for example net assets equal total equity), but a reading error is still possible — check the original accounts at Companies House.

Ratios

2025

Sector comparison

SIC 46460

Where the company stands among the 2,974 active companies whose first SIC code is 46460 (Wholesale of pharmaceutical goods).

Turnover£22,677,000
Lower than 52% · median £23,764,000 among 214 that publish turnover
Net assets£14,175,000
Higher than 94% · median £32,520
Total assets£20,402,000
Higher than 91% · median £255,000
Cash£9,000
Lower than 76% · median £90,159
Company age27.9 years
Older than 85% · median 6.2 years
Largest in this sector by net assets
  1. CSL BEHRING HOLDINGS LIMITED£11bn
  2. VIIV HEALTHCARE UK LIMITED£5.7bn
  3. MCKESSON GLOBAL SOURCING LIMITED£1bn
  4. MCKESSON MEDICAL-SURGICAL SOURCING LIMITED£999.5m
  5. PFIZER LIMITED£984m
  6. ABBOTT LABORATORIES LIMITED£871.8m
  7. GLAXOSMITHKLINE UK LIMITED£779m
  8. UNIKERIS LIMITED£642m
  9. HALEON UK TRADING LIMITED£554.8m
  10. MUNDIPHARMA MEDICAL COMPANY LIMITED£461.7m

Positions are approximate. Figures come from each company's latest accounts; money and employee figures are compared only with companies that filed accounts in pounds for a period ending in the last two and a half years and are not dormant, so those groups are smaller than 2,974. The line on each bar marks the median.

Summary: NAPP PHARMACEUTICALS LIMITED

What kind of company is it?

NAPP PHARMACEUTICALS LIMITED is a private limited company registered with Companies House under company number 03690299. It was incorporated on 22 Dec 1998. Its status is active. The registered office is in Cambridge (CB4). Its nature of business (SIC 2007) is wholesale of pharmaceutical goods (46460).

How is the company doing financially?

The latest accounts in the database are for 2025 (period ending 31 Dec 2025); the company files full accounts. Turnover was £22,677,000. Profit for the year was £301,000. Net assets were £14,175,000, up 3% on the previous year. Cash at bank and in hand was £9,000. Total assets were £20,402,000 and total liabilities £6,227,000. Figures are available for 2 financial years (2024–2025).

How does it compare with similar companies?

Compared with 2,974 active companies whose first SIC code is 46460: By turnover it ranks lower than 52% of the 214 that publish turnover (median £23,764,000). By net assets it ranks higher than 94% of them (median £32,520). By total assets it ranks higher than 91% of them (median £255,000). By cash it ranks lower than 76% of them (median £90,159). It is older than 85% of them (median age 6.2 years).

Does it supply the public sector?

The company is named as a supplier in 41 public contract award notices from 7 public sector buyers since 2018. Contracts awarded to it alone have a combined published value of £526m. Its most frequent buyer is NHS England (28 contracts). 22 of the awards are shared with other suppliers, typically framework agreements.

What do public registers and reports show?

In its latest payment practices report it took an average of 49 days to pay suppliers, and 6% of invoices were not paid within agreed terms.

Who runs and controls the company?

One person with significant control is registered. 1 of 2 registered charges are outstanding.

When are its next filings due?

The next accounts are due by 30 Sep 2027. The next confirmation statement is due by 12 Jun 2027.

Filed accounts2024–2025
2024 †2025 †
Turnover24,886,00022,677,000
Profit for the year3,797,000301,000
Cash at bank and in hand11,0009,000
Total assets20,642,00020,402,000
Total liabilities6,877,0006,227,000
Net assets / total equity13,765,00014,175,000
Average number of employees31—

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Public contracts

41 contracts

NAPP PHARMACEUTICALS LIMITED is named as a supplier in 41 public contract award notices from 7 public sector buyers since 2018. The 2 contracts awarded to it alone with a published value add up to £526m. 22 awards are shared with other suppliers and not counted in that total.

Contracts per year
Main buyers7
NHS England
28 contracts · £526m
The NHS Commissioning Board (operating under the name of NHS England)
6 contracts
Regional Business Services Organisation, Procurement and Logistics Service
2 contracts · £13.3k
ATAMIS LTD
2 contracts
NHS England and NHS Improvement
1 contract
Contracts
  1. NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026‡NHS England · shared by 25 suppliers, up to £1,330,779,176 in total · 2 lots · runs until Aug 2028
  2. NHS National Branded Interim - 1 June 2026‡NHS England · shared by 51 suppliers, up to £529,090,780 in total · runs until Apr 2028
  3. Generic, Branded Generic & Proprietary Medicinal Products - Group 18Regional Business Services Organisation, Procurement and Logistics Service · £13,310
  4. NP40925 Analgesics, Anaesthetics, Musculoskeletal & Joint Disease Medicines‡The Common Services Agency (more commonly known as NHS National Services Scotland) ("the… · shared by 7 suppliers, up to £704,484 in total · 7 lots
  5. NHS Branded Medicines Tranche A - London & SOFE & Adult Influenza National‡NHS England · shared by 28 suppliers, up to £261,895,933 in total · runs until Aug 2027
Show 36 more
  1. NHS Framework Agreement for Branded Medicines – Tranche A London and South of England and Adult Influenza (National) - 01 September 2025‡NHS England · £1
  2. Medicinal Products and Pharma Funded Homecare [5749446]‡Regional Business Services Organisation Procurement and Logistics Service · shared by 31 suppliers, up to £210,000,000 in total
  3. NHS Framework Agreement for Branded Medicines - Proprietary Category Tender‡NHS England · shared by 72 suppliers, up to £1,241,520,444 in total · runs until Apr 2029
  4. NHS Framework Agreement for Branded Medicines - Proprietary Category Tender - 1 May 2025‡NHS England · £1
  5. NHS Branded Medicines Tranche Framework for London and South of England‡NHS England · £1
  6. NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024‡NHS England · £1
  7. NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024‡NHS England · £2 · 2 lots
  8. NHS South of England Branded Medicines - Tranche A - September 2023‡NHS England · £1
  9. NHS Framework Agreement-Branded Medicines - National Proprietary Pharmaceuticals‡NHS England · shared by 50 suppliers, up to £304,504,000 in total
  10. NHS Framework Agreement for Branded Medicines - National Proprietary Pharmaceuticals‡NHS England · £1
  11. NHS National Pharmaceuticals Transition 2022_1‡NHS England and NHS Improvement · shared by 42 suppliers, up to £79,272,690 in total · 2 lots
  12. NHS National Pharmaceuticals Transition 2022_1‡NHS England · £1
  13. NHS Framework Agreement for Branded Medicines - National Tender‡NHS England · £1
  14. NHS Framework for Midlands and East, Branded Medicines - Tranche A and Annual‡NHS England · shared by 31 suppliers, up to £216,078,796 in total
  15. NHS Framework for the North of England, Branded Medicine‡NHS England · shared by 31 suppliers, up to £716,741,676 in total · 3 lots
  16. NHS Framework for the North of England, Branded Medicine‡The NHS Commissioning Board (operating under the name of NHS England) · £2 · 2 lots
  17. NHS Framework for Midlands and East, Branded Medicines – Tranche A and Annual‡The NHS Commissioning Board (operating under the name of NHS England) · £2 · 2 lots
  18. NHS National Generic Pharmaceuticals Wave 13‡ATAMIS LTD · shared by 100 suppliers, up to £939,483,068 in total · 2 lots
  19. NHS National Generic Pharmaceuticals Wave 13‡ATAMIS LTD · shared by 99 suppliers, up to £469,741,550 in total
  20. NHS National Generic Pharmaceuticals Wave 13‡The NHS Commissioning Board (operating under the name of NHS England) · £1
  21. NHS National Pharmaceuticals Transition 2021_3‡NHS England · shared by 36 suppliers, up to £25,983,607 in total
  22. NHS Framework Agreement for Branded Medicines – National‡NHS England · £526,000,000
  23. NHS National Pharmaceuticals Transition 2021_3‡The NHS Commissioning Board (operating under the name of NHS England) · £1
  24. NHS Framework Agreement, Branded Medicines for London and South of England‡NHS England · £1,117,043,852 · 5 lots
  25. Medicinal Products and Pharma Funded Homecare Services‡Procurement and Logistics Service · shared by 29 suppliers, up to £93,103,448 in total · 3 lots
  26. NHS Framework, North of England, Branded Medicines-Tranche A and Annual TrancheNHS England · £1
  27. NHS Framework, North of England, Branded Medicines - Tranche A and Annual Tranche‡The NHS Commissioning Board (operating under the name of NHS England) · £2 · 2 lots
  28. NHS Framework for the Midlands and East, Branded Medicines - Tranche BNHS England · shared by 37 suppliers, up to £228,156,862 in total
  29. NHS Framework for the Midlands and East, Branded Medicines – Tranche B plus Cytokine Modulators and other Monoclonal Antibodies.‡The NHS Commissioning Board (operating under the name of NHS England) · £2 · 2 lots
  30. NHS Framework for the NHS London Region, Branded Medicines - Tranche ANHS England · shared by 28 suppliers, up to £191,062,951 in total
  31. NHS Midlands and East Branded Medicines - Tranche ANHS England · shared by 27 suppliers, up to £418,787,000 in total
  32. NHS South of England Branded Medicines - Tranche A - Contracts Finder Award NoticeNHS England · shared by 26 suppliers, up to £188,004,961 in total
  33. NHS Framework Agreement for Branded medicines - London - Tranche B - Contracts Finder OpportunityNHS England · shared by 30 suppliers, up to £251,930,337 in total
  34. NHS England Framework Agreement: South of England (Tranche B)‡NHS England · shared by 32 suppliers, up to £501,400,000 in total
  35. NHS Framework Agreement for Trastuzumab InjectionNHS England · shared by 4 suppliers, up to £226,961,206 in total
  36. NHS Framework Agreement - North of England - Tranche B‡NHS England · shared by 30 suppliers, up to £1,042,200,000 in total · 2 lots

From contract award notices on Contracts Finder (since 2016) and Find a Tender (since 2021), published by the Cabinet Office under the Open Government Licence v3.0. Values are as published by the buyer and usually cover the whole contract term; the total leaves out awards shared between several suppliers, where the published figure is a ceiling for all of them, placeholder values and single figures of £1 billion or more. Notices marked ‡ do not state a company number and were linked by an exact match on the registered name. Contracts below the publication thresholds and those of devolved buyers that publish elsewhere are not included.

Statutory reporting

Payment practices1 Jan 2024 – 30 Jun 2024
Average time taken to pay invoices
49 days
Invoices not paid within agreed terms
6%
Member of a payment code
No
  • Within 30 days 23%
  • 31 to 60 days 56%
  • After 60 days 21%
Earlier periods (7)
Period ending
Days to pay
Within 30 days
Late
31 Dec 2023
27
70%
15%
30 Jun 2023
29
70%
1%
31 Dec 2022
43
45%
51%
30 Jun 2022
33
58%
34%
31 Dec 2021
33
52%
53%
30 Jun 2021
37
30%
71%
31 Dec 2020
35
38%
67%

View the latest report on GOV.UK

Figures the company reported itself to the government's Check payment practices service, Gender pay gap service and Modern slavery statement registry (Open Government Licence v3.0). Only large companies and employers with 250 or more staff have to report, so most companies have nothing here.

History

4 events
  1. Financial year 2025 endedAccounts: turnover £22.7m, net assets £14.2m
  2. Financial year 2024 endedAccounts: turnover £24.9m, net assets £13.8m, 31 employees
  3. Napp Pharmaceutical Holdings Limited registered as a person with significant control
  4. Company incorporatedPrivate limited company

Dates as recorded at Companies House: incorporation, name changes, officer appointments and resignations, current persons with significant control, and the end of each financial year with figures in the database. Former persons with significant control are not listed.